Anti-VEGF injections of bevacizumab

Phase 3Monoclonal antibody

FFondation Ophtalmologique Adolphe de Rothschild

Anti-VEGF injections of bevacizumab is one of 4 small molecule programs targeting Coats disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coats DiseaseActive, not recruiting

Coats DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Coats Disease

#DrugCompanyPhaseTrials

Avastin

Retaane

Anti-VEGF injections of bevacizumab

FFondation Ophtalmologique Adolphe de Rothschild

Phase 3

1 4

Lucentis

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Coats disease1 trial

Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease

Terminated·FFondation Ophtalmologique Adolphe de Rothschild·Phase 3·NCT03940690·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anti-VEGF injections of bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-VEGF injections of bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-VEGF injections of bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fondation Ophtalmologique Adolphe de Rothschild company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: FFondation Ophtalmologique Adolphe de Rothschild

Anti-VEGF injections of bevacizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Coats disease1 trial

References

Drug Info

Quick Facts

Related News